The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study

Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) is now available in limited settings in Canada. Methods: A prospective open-label 2-year observational pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez, G. G., Van Dyk, D., Mallick, R., Lesperance, S., Demaio, P., Finn, S., Potvin, S. Edmunds, Patterson, M., Pease, C., Amaratunga, K., Hui, C., Cameron, D.W., Mulpuru, S., Aaron, S.D., Momoli, F., Zwerling, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241515/
https://www.ncbi.nlm.nih.gov/pubmed/32379538
http://dx.doi.org/10.1080/22423982.2020.1758501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241515/
https://www.ncbi.nlm.nih.gov/pubmed/32379538
http://dx.doi.org/10.1080/22423982.2020.1758501

Ejemplares similares